Slide Source: Lipids Online Slide Library www.lipidsonline.org ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Slides:

Advertisements

Similar presentations

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.

Advertisements

1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.

Effect of Rosuvastatin Therapy on Coronary Artery Stenosis Assessed by Quantitative Coronary Angiography in ASTEROID CM Ballantyne, 1 JS Raichlen, 2 SJ.

New Approaches to LDL Reduction Cholesterol Absorption Inhibitors.

Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease Michael Miller,

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Lipids: Is Lower Better For Diabetic Patients? Prof. Samir Helmy Assaad -Khalil Department of Internal Medicine Unit of Diabetes, Lipidology & Metabolism.

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Downloaded from Slide 1 Ezetimibe Coadministered with Atorvastatin in Patients with Hypercholesterolemia and Coronary Heart.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden References Nissen et al. Effect.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

The REVERSAL Trial Reversing Atherosclerosis With Aggressive Lipid Lowering.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,

A Diabetes Outcome Progression Trial

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Results of the First Major Clinical Trial of An Oral Agent Inducing ApoA-I Synthesis: A New Approach to Raising HDL and CV Risk Modification SJ Nicholls,

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Dual Lipid-Lowering Strategy With Ezetimibe.

Copyleft Clinical Trial Results. You Must Redistribute Slides ASTEROID Trial A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived.

Copyright © 2006 American Medical Association. All rights reserved.

The American College of Cardiology Presented by Dr. Steven E. Nissen

Baseline characteristics and effectiveness results

CIMT: a Useful Surrogate for Assessing the Efficacy of new Cardiovascular Drugs? Daniel H. O’Leary, M.D.

The American Heart Association Presented by Dr. Steven E. Nissen

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Dyslipidemia and the Risk of Developing Hypertension in a Working‐Age Male Population by Toshiaki Otsuka, Hirotaka Takada, Yasuhiro Nishiyama, Eitaro Kodani,

The ASSERT Study.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Section 7: Aggressive vs moderate approach to lipid lowering

Stephen J. Nicholls, MBBS, PhD; E

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Flow of Patients Through the Trial

Flow of Patients Through Trial

Baseline Characteristics, Blood Pressures, and Laboratory Values

Disposition of Patients in the Atherogenic Dyslipidemia Study

PROSPER: trial design

James H O'Keefe, Jr et al. JACC 2004;43:

Presentation transcript:

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing (n=158) Age, years (mean)58.5 Male70.2%72.8% Weight, kg (mean) Body mass index (median) History of hypertension96.0%93.7% History of diabetes mellitus13.2%11.4% Concomitant Medications Aspirin83.7%83.5% ACE inhibitors53.3%45.6% Angiotensin receptor antagonists 18.3%13.3% Organic nitrates85.1%87.3% Beta-blockers84.2%73.4% Nissen SE et al. JAMA 2006;295:

Slide Source: Lipids Online Slide Library Lipid Values and Percent Change (n=346) Mean Baseline Mean during Treatment Percent Change p Value Total cholesterol (mg/dL) –33.8<0.001 LDL-C (mg/dL) –53.2<0.001 HDL-C (mg/dL) <0.001 Triglycerides (mg/dL) –14.5<0.001 LDL-C/HDL-C ratio3.21.3–58.5<0.001 Nissen SE et al. JAMA 2006;295:

Slide Source: Lipids Online Slide Library Dual Primary IVUS Efficacy Parameters Regression p<0.001* –0.79 *Wilcoxon signed rank test for comparison with baseline Change in Percent Atheroma Volume (%) Change in Percent Atheroma Volume (mm 3 ) –5.6 Regression p<0.001* Nissen SE et al. JAMA 2006;295: Median Change in Percent Atheroma Volume Median Change in Most Diseased Subsegment

Slide Source: Lipids Online Slide Library Recent Coronary IVUS Progression Trials Relationship Between LDL-C and Progression Rate Median Change in Percent Atheroma Volume (%) Mean LDL-C (mg/dL) ASTEROID rosuvastatin R 2 = 0.95 p<0.001 CAMELOT placebo REVERSAL pravastatin ACTIVATE placebo A-Plus placebo REVERSAL atorvastatin Nissen SE et al. JAMA 2006;295: